mechanisms of resistance using PDO and pretreatment biopsy specimen

Exploratory Research
- Evaluate PFS, safety and tolerability, ORR, DCR, and OS in patients who received prior treatment with 5-FU independently from the entire population

Contact: Amit Mahipal, MBBS, MPH • 612-298-5401 • mahipal.amit@mayo.edu

Coordinator: Jaclyn Wessling, MS • 507-538-4545 • wessling.jaclynn@mayo.edu

ClinicalTrials.gov Identifier: NCT04072445

ERRATUM


In the August 2021 issue of JNCCN, the NCCN Guidelines Insights on Uterine Neoplasms, Version 3.2021 (J Natl Compr Canc Netw 2021;19[8]:888–895) was published with an error.

The list of supporters for the Continuing Education Activity, printed on page 888, was incorrect. The correct list of supporters should read: This activity is supported by educational grants from Agios Pharmaceuticals; AstraZeneca; Clovis Oncology, Inc.; Daiichi Sankyo; Eisai; Epizyme Inc.; Novartis; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. This activity is supported by an independent medical education grant from Bristol-Myers Squibb, and Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is supported by an independent educational grant from Mylan Inc. This activity is supported by a medical education grant from Karyopharm Therapeutics.

A corrected copy of the article is available online at JNCCN.org. The editorial office apologizes for this error.